Advanced Prostate Cancer

/Advanced Prostate Cancer

Urologists Fail to Complete Psycho-Social and Sexual Histories of Prostate Cancer Patients

Malecare and the University of Minnesota collaborated on the first study to investigate what gay and bisexual men are offered and what they try as rehabilitation to address the sexual and urinary effects of prostate cancer treatment.   Gay and bisexual men with prostate cancer (N=193) from Malecare's online and in-person support groups completed survey questions asking [...]

By | April 26th, 2017|Advanced Prostate Cancer, Gay, Newly Diagnosed|0 Comments

Biopsy Slides Can Now Be Digitalized and Reviewed by Pathologists

The first whole slide imaging (WSI) system that allows for review and interpretation of digital prostate cancer pathology slides prepared from biopsied tissue has been approved by the U.S. Food and Drug Administration (FDA). Malecare is a leading advocate of second and third opinions of prostate cancer pathology from biopsy samples. The logistics of shipping and [...]

By | April 25th, 2017|Advanced Prostate Cancer|0 Comments

Blood Test Determines Effectiveness of Zytiga and or Xtandi, Before You Begin Treatment.

Adna is a new blood test that will tell you if Zytiga and Xtandi will or will not treat castration resistant prostate cancer. Imagine knowing if Zytiga and or Xtandi will fail to help you, before you spend months of time and thousands of dollars trying these drugs out. The test, called AdnaTest Prostate Cancer Panel [...]

By | April 21st, 2017|Advanced Prostate Cancer|1 Comment

HSD3B1 gene makes Androgen Deprivation Therapy (ADT) less effective

An inherited genetic change, HSD3B1 gene causes Androgen Deprivation Therapy (ADT) to be less effective for treating metastatic prostate cancer. Physician-researcher Nima Sharifi, M.D. published this finding in the October, 2016 The Lancet Oncology.  While Androgen Deprivation Therapy is effective for many men with advanced stage prostate cancer, prostate tumors eventually become resistant to ADT because the tumors make their own androgens.  “A simple blood [...]

By | April 20th, 2017|Advanced Prostate Cancer|0 Comments

A New Steroid for Treating Advanced Prostate Cancer

E4 is a steroid that may become a treatment for advanced prostate cancer, both alone and fin combination with hormone therapy. Ellen Dutman, MSc, a clinical researcher, studied E4 as a treatment to lower testosterone. “An important advantage of E4 is expected to be the avoidance of the hypoestrogenic side effects that occur with other [...]

By | April 18th, 2017|Advanced Prostate Cancer|0 Comments

Androgen Deprivation and Dementia “Might” be Linked

Androgen deprivation therapy (ADT, or, “hormone therapy”) may be linked to increased risk of having dementia. Researchers, Nead, Sinha and Nguyen reviewed nine studies by other researchers. Seven of those studies reported an adjusted effect estimate for dementia risk. That means that a majority of today’s evidence based research says that ADT and dementia probably [...]

By | April 17th, 2017|Advanced Prostate Cancer|0 Comments

Yervoy ( Ipilimumab ) Useless When Used By Itself

Yervoy (ipilimumab) alone doesn’t help treat advanced prostate cancer patients. Yervoy activates the immune system by going after the CTLA-4 protein receptor that slows immune-system activity. But prostate cancer responds to Yervoy by increasing two other immune checkpoint molecules, PD-L1 and VISTA. And both send a don’t-eat-me signal to immune cells. That reaction is why Yerboy, by [...]

By | April 10th, 2017|Advanced Prostate Cancer|0 Comments

Selective Androgen Receptor Degraders May Become New Treatment for Castration Resistant Prostate Cancer

New molecules called selective androgen receptor degraders (SARDs) might be helpful in fighting advanced prostate cancer, according to an industry-sponsored study presented April 1, at the 99th annual meeting of the Endocrine Society. "If successful in the clinic, the novel highly potent SARDs discovered in this program could be used to treat many of the [...]

By | April 7th, 2017|Advanced Prostate Cancer|0 Comments

Estrogen As New Prostate Cancer Treatment

Fetal estrogen estetrol, also called E4, is being tested in the Netherlands as a treatment for advanced prostate cancer. "E4 for the treatment of prostate cancer would offer a new and affordable option compared to current standard and new therapies. An important advantage of E4 is expected to be the avoidance of the hypoestrogenic side [...]

Androgen Deprivation Therapy (ADT) may not be the best way to fight advanced prostate cancer

Researchers from the University and the Sichuan Antibiotics Industrial Institute in China have discovered a novel treatment for advanced prostate cancer. For over forty years, ADT has been the foundation of advanced stage prostate cancer treatment. ADT is effective initially, most often measured by a drop in PSA measurement. But in almost all cases, prostate [...]

By | March 15th, 2017|Advanced Prostate Cancer, Hormone Therapy, Uncategorized|0 Comments